155 related articles for article (PubMed ID: 23770244)
1. PLK1 signaling in breast cancer cells cooperates with estrogen receptor-dependent gene transcription.
Wierer M; Verde G; Pisano P; Molina H; Font-Mateu J; Di Croce L; Beato M
Cell Rep; 2013 Jun; 3(6):2021-32. PubMed ID: 23770244
[TBL] [Abstract][Full Text] [Related]
2. Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.
Bhola NE; Jansen VM; Bafna S; Giltnane JM; Balko JM; Estrada MV; Meszoely I; Mayer I; Abramson V; Ye F; Sanders M; Dugger TC; Allen EV; Arteaga CL
Cancer Res; 2015 Jan; 75(2):405-14. PubMed ID: 25480943
[TBL] [Abstract][Full Text] [Related]
3. Identification of fibroblast growth factor-8b target genes associated with early and late cell cycle events in breast cancer cells.
Nilsson EM; Brokken LJ; Narvi E; Kallio MJ; Härkönen PL
Mol Cell Endocrinol; 2012 Jul; 358(1):104-15. PubMed ID: 22465097
[TBL] [Abstract][Full Text] [Related]
4. Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.
Lin YC; Sun SH; Wang FF
Cell Signal; 2011 Nov; 23(11):1816-23. PubMed ID: 21726628
[TBL] [Abstract][Full Text] [Related]
5. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR
Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192
[TBL] [Abstract][Full Text] [Related]
6. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs.
Spänkuch B; Kurunci-Csacsko E; Kaufmann M; Strebhardt K
Oncogene; 2007 Aug; 26(39):5793-807. PubMed ID: 17369857
[TBL] [Abstract][Full Text] [Related]
7. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.
Lee C; Fotovati A; Triscott J; Chen J; Venugopal C; Singhal A; Dunham C; Kerr JM; Verreault M; Yip S; Wakimoto H; Jones C; Jayanthan A; Narendran A; Singh SK; Dunn SE
Stem Cells; 2012 Jun; 30(6):1064-75. PubMed ID: 22415968
[TBL] [Abstract][Full Text] [Related]
8. Essential Role of Polo-like Kinase 1 (Plk1) Oncogene in Tumor Growth and Metastasis of Tamoxifen-Resistant Breast Cancer.
Jeong SB; Im JH; Yoon JH; Bui QT; Lim SC; Song JM; Shim Y; Yun J; Hong J; Kang KW
Mol Cancer Ther; 2018 Apr; 17(4):825-837. PubMed ID: 29437878
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z
Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492
[TBL] [Abstract][Full Text] [Related]
10. Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer.
Maire V; Némati F; Richardson M; Vincent-Salomon A; Tesson B; Rigaill G; Gravier E; Marty-Prouvost B; De Koning L; Lang G; Gentien D; Dumont A; Barillot E; Marangoni E; Decaudin D; Roman-Roman S; Pierré A; Cruzalegui F; Depil S; Tucker GC; Dubois T
Cancer Res; 2013 Jan; 73(2):813-23. PubMed ID: 23144294
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of Polo-like kinase 1 induces cellular senescence in human primary cells through a p53-dependent pathway.
Kim HJ; Cho JH; Kim JR
J Gerontol A Biol Sci Med Sci; 2013 Oct; 68(10):1145-56. PubMed ID: 23525475
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
Spänkuch B; Heim S; Kurunci-Csacsko E; Lindenau C; Yuan J; Kaufmann M; Strebhardt K
Cancer Res; 2006 Jun; 66(11):5836-46. PubMed ID: 16740723
[TBL] [Abstract][Full Text] [Related]
13. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-191, an estrogen-responsive microRNA, functions as an oncogenic regulator in human breast cancer.
Nagpal N; Ahmad HM; Molparia B; Kulshreshtha R
Carcinogenesis; 2013 Aug; 34(8):1889-99. PubMed ID: 23542418
[TBL] [Abstract][Full Text] [Related]
15. Tumor inhibition by genomically integrated inducible RNAi-cassettes.
Kappel S; Matthess Y; Zimmer B; Kaufmann M; Strebhardt K
Nucleic Acids Res; 2006; 34(16):4527-36. PubMed ID: 16945954
[TBL] [Abstract][Full Text] [Related]
16. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy.
Tan J; Li Z; Lee PL; Guan P; Aau MY; Lee ST; Feng M; Lim CZ; Lee EY; Wee ZN; Lim YC; Karuturi RK; Yu Q
Cancer Discov; 2013 Oct; 3(10):1156-71. PubMed ID: 23887393
[TBL] [Abstract][Full Text] [Related]
17. Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells.
Francescangeli F; Patrizii M; Signore M; Federici G; Di Franco S; Pagliuca A; Baiocchi M; Biffoni M; Ricci Vitiani L; Todaro M; De Maria R; Zeuner A
Stem Cells; 2012 Sep; 30(9):1819-30. PubMed ID: 22753241
[TBL] [Abstract][Full Text] [Related]
18. A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis.
Reindl W; Yuan J; Krämer A; Strebhardt K; Berg T
Chembiochem; 2009 May; 10(7):1145-8. PubMed ID: 19350612
[TBL] [Abstract][Full Text] [Related]
19. Polo-like kinases in AML.
Berg T; Bug G; Ottmann OG; Strebhardt K
Expert Opin Investig Drugs; 2012 Aug; 21(8):1069-74. PubMed ID: 22667760
[TBL] [Abstract][Full Text] [Related]
20. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
